AstraZeneca’s Baxdrostat Demonstrates significant Blood Pressure Reduction in Treatment-Resistant Hypertension – Phase III Trial Results
(RTTNews) – AstraZeneca PLC (AZN, AZN.L) today announced positive results from its Phase III Bax24 trial, showing baxdrostat substantially lowered 24-hour systolic blood pressure (SBP) in patients with treatment-resistant hypertension (rHTN). The trial revealed a placebo-adjusted reduction of 14 mmHg in ambulatory 24-hour average SBP.
The Bax24 trial evaluated patients with rHTN receiving either 2mg of baxdrostat or a placebo alongside their existing standard care. Researchers observed efficacy throughout the entire 24-hour period, including during early morning hours, a time associated with increased cardiovascular risk. Baxdrostat successfully met its primary endpoint, demonstrating consistent and clinically meaningful blood pressure reductions after 12 weeks of treatment. The drug was also generally well-tolerated, with a safety profile consistent with findings from the earlier BaxHTN trial.
Beyond the primary endpoint, baxdrostat achieved statistically significant improvements in key secondary endpoints, including reductions in night-time average SBP and seated SBP. Notably, 71% of patients treated with baxdrostat achieved an ambulatory 24-hour average SBP below 130 mmHg, compared to only 17% in the placebo group. These results suggest baxdrostat holds significant promise for improving treatment outcomes for patients with difficult-to-control hypertension.
For more Such Health news, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
